Pharmaceutical design of a new lactose-free coprocessed excipient: application of hydrochlorothiazide as a low solubility drug model

References

• Bolhuis GK, Armstrong NA. (2006). Excipients for direct compaction–an update. Pharm Dev Technol, 11:111–124.
   PubMed Web of Science ®Google Scholar
• Jivraj II, Martini LG, Thomson CM. (2000). An overview of the different excipients useful for the direct compression of tablets. Pharm Sci Technol Today, 3:58–63.
   PubMedGoogle Scholar
• Shangraw RF, Demarest DA. (1993). A survey of current industrial practices in the formulation and manufacture of tablets and capsules. Pharm Technol. January, 32–44.
   Google Scholar
• Armstrong NA. (1976). Criteria for assessing direct compression diluents. Manuf Chem. December, 29–31.
   Google Scholar
• Brittain HG. (1996). Physical powder compaction of pharmaceutical solids. In: Bolhuis GKChowhan ZT, Materials for direct compression. G. Alderborn C. Nyström, Editors, Pharmaceutical Powder Compaction Technology, Marcel Dekker, New York. 419–500.
   Google Scholar
• Ibrahim YK, Olurinola PF. (1991). Comparative microbial contamination levels in wet granulation and direct compression methods of tablet production. Pharm Acta Helv, 66:298–301.
   PubMedGoogle Scholar
• Reimerdes D . (1993). The Near Future of Tablet Excipients. Manufacturing chemist, 64:14–15.
   Google Scholar
• Moreton RC. (1996). Tablet excipients to the year 2001: a look into the crystal ball. Drug Dev Ind Pharm. 22, 11–23.
   Web of Science ®Google Scholar
• Baykara T, Duman G, Ozesener KS, Ordu S, Ozates B. (1991). Comparing the compressibility of Ludipress with the other direct tabletting agents by using acetaminophen as an active ingredient. Drug Dev Ind Pharm. 17, 2359–2371.
   Web of Science ®Google Scholar
• Kolter K, Heinz R, Fussnegger B. (1999). Compression properties of Ludipress LCE a new direct compression excipient. Technical Information MER 9932. BASF: Ludwigshafen (germany).
   Google Scholar
• Kolter K, Heinz R, Fussnegger B. (2003). Ludipress LCE a new direct compression excipient. Excipient sans Actives for Pharma. 10, 2–3.
   Google Scholar
• Armstrong NA, Roscheisen G, Al-Aghbar MR. (1996). Cellactose as a tablet diluents. Manuf Chem. 67, 25–26.
   Google Scholar
• Garr JS, Rubinstein MH. (1991). Compaction properties of cellulose-lactose direct compression excipient. Pharm Tech Int. 3, 24–27.
   Google Scholar
• Reimerdes D, Aufmuth KP. (1992). Tableting with co-processed lactose-cellulose excipients. Manuf Chem. 63, 21–24.
   Google Scholar
• MicroceLac 100. Expert tableting. Technical Bulletin. Meggle Pharma: 1–9.
   Google Scholar
• Sherwood BE, Becker JW. (1998). A new class of high functionality excipient: silicified microcrystalline cellulose. Pharm Technol. 22, 78–88.
   Google Scholar
• Gierer DS. Patent application 20030004182, assigned to Pfizer Inc. 23 April 2002.
   Google Scholar
• Hjorth TB et al. Patent application 20030050312, assigned to Novo Nordisk. 12 March 2002.
   Google Scholar
• Liljegren K et al. Patent application 20030109577, assigned to Ludbeck H A/S. 5 December. 2000.
   Google Scholar
• Hauschild K, Picker KM. (2004). Evaluation of a new co-processed compound based on lactose and maize starch for tablet formulation. AAPS Pharm Sci. 6: article 16.
   PubMedGoogle Scholar
• Bavitz JF, Schwartz JB. (1974). Direct compression vehicles: evaluation of some common diluents on compression. D&CI. 114, 44–52.
   Google Scholar
• Ohno S, Ikeda M. (1986). Excipient composition. GB2172006A. September 10th.
   Google Scholar
• Ohno S, Ikeda M. (1991). Excipients for use in compression holding and process of preparation. US patent 5 028633. July 2nd.
   Google Scholar
• Avachat A, Ahire VJ. (2007). Characterization and evaluation of spray dried co-processed excipients and their application in solid dosage forms. Indian J Pharm Sci. 69, 85–90.
   Google Scholar
• Lieberman HA, Lachman L. Pharmaceutical Dosage Form, Vol. 1, Marcel Dekker, New York, 1980, p. 210–215.
   Google Scholar
• Villafuerte S. 1995. Compactibility of ternary mixtures of pharmaceutical powders. Pharmaceutica Acta Helvetiae, 70, 329–337.
   Google Scholar
• European Pharmacopoeia, sixth ed., vol. 6.0, Council of Europe, Strasbourg (France), 2008.
   Google Scholar
• Le Hir A. (1995b). Farmacia galénica. 6ed. París. Masson. 243.
   Google Scholar
• Box GEP, Behnken DW. (1960). Some new 3 level designs for the study of quantitative variables. Technometrics. 2, 455–475.
   Google Scholar
• Derringer GC, Suich R. (1980). Simultaneous optimization of several response variables. J Quality Technology 12, 214–219.
   Web of Science ®Google Scholar
• Harrington EC. (1965). The desirability function. Industrial Quality Control. April, 494–498.
   Google Scholar
• Pérez P, Suñé-Negre JM, Miñarro M, Roig M, Fuster R, García-Montoya E et al. (2006). A new expert systems (SeDeM diagram) for control batch powder formulation and preformulation drug products. Eur J Pharm Biopharm, 64:351–359.
   PubMed Web of Science ®Google Scholar
• Suñé JM, Roig M, Fuster R, Hernández C, Pérez P, Ruhí R. (2005). Nueva metodología de preformulación galénica para la caracterización de sustancias en relación a su viabilidad para la compresión: diagrama SeDeM. Cien Technol Pharm. 3, 125–136.
   Google Scholar
• Font Quer P. (1962). Medicamenta. 6ª edición. Editorial Labor SA. Barcelona. 340–341.
   Google Scholar
• Guyot JC, Tête L, Talk S. (1992). Practical interest of the cohesion index for the techonological formulation of tablets. Cog Int Technol Pharm, 6t, APGI, Paris, 246–254.
   Google Scholar
• United States Pharmacopeia and National Formulary (USP 29 - NF 24). Rockville, MD: US Pharmacopeia;2006;1205.
   Google Scholar
• International Conference on Harmonization. Validation of analytical procedures: methodology. 1998.
   Google Scholar
• Yamaoka K, Makaowa T, Uno T. (1978). Application of Akaike’s information criteria (AIC) in the evaluation of linear pharmacokinetics equation. J Pharmacokinetic Biopharm. 6, 167–175.
   Google Scholar